Swiss National Bank Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swiss National Bank cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 362,600 shares of the biopharmaceutical company's stock after selling 12,800 shares during the quarter. Swiss National Bank owned approximately 0.28% of Alnylam Pharmaceuticals worth $85,323,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Allworth Financial LP boosted its position in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 38 shares in the last quarter. Nixon Peabody Trust Co. increased its holdings in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after purchasing an additional 43 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares in the last quarter. IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares in the last quarter. Finally, Nwam LLC lifted its stake in Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after acquiring an additional 50 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

ALNY has been the subject of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a "neutral" rating in a report on Tuesday, March 11th. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Finally, Chardan Capital restated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $304.26.

Alnylam Pharmaceuticals Trading Up 3.7 %

ALNY stock traded up $9.14 during midday trading on Wednesday, reaching $253.44. 987,375 shares of the company traded hands, compared to its average volume of 789,886. The firm has a market capitalization of $32.81 billion, a price-to-earnings ratio of -116.79 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The business has a 50 day moving average of $255.73 and a 200-day moving average of $259.59. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.